Recent developments with Teva- Pharmaceutical Industries Ltd. ADR (TEVA) have led to the company’s beta value being reach 0.88 cents.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) on Monday, soared 3.21% from the previous trading day, before settling in for the closing price of $17.46. Within the past 52 weeks, TEVA’s price has moved between $8.06 and $19.08.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has dropped its sales by -2.68% annually for the last half of the decade. The company achieved an average annual earnings per share of -4.46%. With a float of $1.13 billion, this company’s outstanding shares have now reached $1.13 billion.

In an organization with 37226 employees, it is important to assess its efficiency.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Insider and Institutional Ownership

Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Teva- Pharmaceutical Industries Ltd. ADR is 0.01%, while institutional ownership is 54.44%. The most recent insider transaction that took place on Aug 12 ’24, was worth 1,711,447. In this transaction Exec. VP, European Commercial of this company sold 98,943 shares at a rate of $17.30, taking the stock ownership to the 0 shares. Before that another transaction happened on Aug 09 ’24, when Company’s EVP, Business Development sold 4,065 for $17.28, making the entire transaction worth $70,243. This insider now owns 8,848 shares in total.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Latest Financial update

#####

According to the Wall Street analysts, stocks earnings will be around -4.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.60% during the next five years compared to 26.63% growth over the previous five years of trading.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is currently performing well based on its current performance indicators. A quick ratio of 0.59 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.25. Likewise, its price to free cash flow for the trailing twelve months is 9.84.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.39, a number that is poised to hit 0.66 in the next quarter and is forecasted to reach 2.78 in one year’s time.

Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)

Let’s dig in a bit further. During the last 5-days, its volume was 5.76 million. That was inferior than the volume of 9.8 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 49.35%. Additionally, its Average True Range was 0.46.

During the past 100 days, Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) raw stochastic average was set at 76.65%, which indicates a significant increase from 64.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.69% in the past 14 days, which was lower than the 35.96% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $17.74, while its 200-day Moving Average is $14.92. However, in the short run, Teva- Pharmaceutical Industries Ltd. ADR’s stock first resistance to watch stands at $18.20. Second resistance stands at $18.37. The third major resistance level sits at $18.68. If the price goes on to break the first support level at $17.72, it is likely to go to the next support level at $17.41. The third support level lies at $17.24 if the price breaches the second support level.

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Key Stats

Market capitalization of the company is 20.42 billion based on 1,132,641K outstanding shares. Right now, sales total 15,846 M and income totals -559,000 K. The company made 4,164 M in profit during its latest quarter, and -845,000 K in sales during its previous quarter.